Head and Neck Squamous Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Head and Neck Squamous Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors [Phase 1, Phase 2]
GEN1042 is being evaluated in a Phase 1/2 safety study with indications across malignant solid tumors, including non-small cell lung cancer,…
-
CLINICAL_TRIALS trial_result · 2026-04-08Clinical Trial Update: Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma [Phase 2]
A Phase 2 trial is recruiting to evaluate pembrolizumab with N-803, alone or with PD-L1 t-haNK cells, for resectable head and neck squamous …
-
CLINICAL_TRIALS trial_result · 2026-04-06Clinical Trial Update: Phase 3 Study of PDS0101 and Pembrolizumab in HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Phase 3]
A Phase 3 clinical trial evaluating PDS0101 in combination with pembrolizumab for HPV16-positive recurrent or metastatic head and neck squam…
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors [Phase 1, Phase 2]
Phase 1/Phase 2 trial results for the combination of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) with tislelizumab in advanced solid …
-
CLINICAL_TRIALS trial_result · 2026-04-02Clinical Trial Update: A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours [Phase 1]
Clinical trial update describes a Phase 1 dose-escalation study of [225Ac]-FPI-2068 in adults with advanced solid tumors, currently recruiti…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-03-31Clinical Trial Update: Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma [Phase 2]
Phase 2 trial compares ramucirumab plus pembrolizumab versus pembrolizumab alone in PD-L1 positive recurrent or metastatic head and neck squ…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors [Phase 1]
Phase 1 trial evaluating Nanrilkefusp alfa alone and with pembrolizumab in adults with advanced or metastatic solid tumors; the study (NCT04…
-
CLINICAL_TRIALS trial_result · 2026-03-27Clinical Trial Update: Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck [Phase 2]
A Phase 2 study evaluating the combination of retinfanlimab with INCAGN02385 and INCAGN02390 as first-line therapy for PD-L1-positive recurr…
-
CLINICAL_TRIALS trial_result · 2026-03-25Clinical Trial Update: Exercise Prehabilitation in Patients With Head and Neck Squamous-cell Carcinoma: The FIT4TREAT Trial [NA]
This clinical-trial update reports the FIT4TREAT trial evaluating exercise prehabilitation in patients with head and neck squamous cell carc…
-
CLINICAL_TRIALS trial_result · 2026-03-23Clinical Trial Update: Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma [Phase 1]
Phase 1 study evaluating durvalumab in combination with docetaxel, cisplatin, and 5-fluorouracil for locally advanced head and neck squamous…
-
CLINICAL_TRIALS trial_result · 2026-03-20Clinical Trial Update: Using MASL to Combat Oral Cancer [EARLY_Phase 1]
This update reports the completion and posted results of an early-phase 1 clinical trial evaluating MASL for head and neck squamous cell car…
-
CLINICAL_TRIALS trial_result · 2026-03-18Clinical Trial Update: Radiotherapy in Association With Cetuximab in Patients Treated for an Epidermoid Cancer
This clinical trial update reports the completion of a study evaluating radiotherapy in combination with cetuximab for epidermoid head and n…
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: Hypofractionated Adjuvant Radiotherapy for Resected Head and Neck Cancers [NA]
The document reports completion and posting of results for a trial evaluating hypofractionated adjuvant radiotherapy in resected head and ne…
-
CLINICAL_TRIALS trial_result · 2026-03-17Clinical Trial Update: Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors [Phase 1]
A Phase 1 clinical trial evaluating a gene-modified immune cell therapy after a conditioning regimen for metastatic melanoma and other metas…
-
CLINICAL_TRIALS trial_result · 2026-03-16Clinical Trial Update: Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC [Phase 1]
Phase 1 clinical trial evaluating whether alpha-lipoic acid reduces pain and side effects during concurrent treatment of head and neck squam…
-
CLINICAL_TRIALS trial_result · 2026-03-13Clinical Trial Update: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC [Phase 3]
Phase 3 trial of JNJ-90301900 (NBTXR3) activated by radiotherapy with or without cetuximab for locally advanced head and neck squamous cell …
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: Radiotherapy With Pembrolizumab in Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 2]
Phase 2 trial update evaluating radiotherapy with pembrolizumab for metastatic head and neck squamous cell carcinoma; the study was terminat…
-
CLINICAL_TRIALS trial_result · 2026-03-12Clinical Trial Update: Losartan, Pembrolizumab and Stereotactic Body Radiation Therapy for the Treatment of Patients With Locally Recurrent, Refractory or Oligometastatic Head and Neck Squamous Cell Carcinoma [Phase 1]
This Phase 1 clinical trial is evaluating the combination of losartan, pembrolizumab, and stereotactic body radiation therapy for locally re…
-
CLINICAL_TRIALS trial_result · 2026-03-10Clinical Trial Update: Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) [Phase 1]
Phase 1 clinical trial evaluating the safety and feasibility of Nivolumab-IRDye800CW in patients with head and neck squamous cell carcinoma;…
-
CLINICAL_TRIALS trial_result · 2026-03-05Clinical Trial Update: A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer [Phase 1]
A Phase 1 clinical trial evaluating STRO-004 in adults with refractory or recurrent metastatic cancer is currently recruiting, investigating…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma [Phase 3]
Phase 3 trial comparing RPH-002 with Erbitux (cetuximab) for unresectable metastatic or recurrent head and neck squamous cell carcinoma, foc…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: CIML NK Cell in Head & Neck Cancer [Phase 1]
A Phase 1 trial evaluating CIML NK cells in head and neck squamous cell carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma [Phase 1]
A Phase I comparative study evaluating pharmacokinetics, safety, and preliminary efficacy of RPH-002 versus cetuximab (Erbitux) in unresecta…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Study Evaluating [18F]NOTA-ABY030 for Safety and Tolerability of Indeterminate Primary and/or Metastatic Disease in Head and Neck Squamous Cell Carcinoma [Phase 1]
Phase 1 study evaluating the safety and tolerability of the radiotracer [18F]NOTA-ABY030 in indeterminate primary or metastatic head and nec…
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC [Phase 2]
Phase 2 clinical trial update evaluating molecular residual disease interception in locoregionally advanced HPV+ and HPV- head and neck squa…